Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Pharma Stake Sale On Track, Gains Seen For Contract Business Amid Pandemic

Executive Summary

Piramal Enterprises, which is in the process of fund raising for its pharma business, says it's well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.

You may also be interested in...



Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel